Pds biotech sets significant benchmark in head and neck cancer by achieving extended survival in low pd-l1 expression (cps 1–19) cohort in versatile-002 trial, potentially eliminating need for chemotherapy in the population

First combination therapy to report 29.5 months of median overall survival (mos); standard of care keytruda ® (pembrolizumab) alone (10.8 months) and keytruda ® + chemotherapy (12.3 months) in patients with cps 1-19*
PDSB Ratings Summary
PDSB Quant Ranking